JAMES A BANKSON to Xenograft Model Antitumor Assays
This is a "connection" page, showing publications JAMES A BANKSON has written about Xenograft Model Antitumor Assays.
Connection Strength
0.315
-
In Vivo (19)F-Magnetic Resonance Imaging of Adoptively Transferred NK Cells. Methods Mol Biol. 2016; 1441:317-32.
Score: 0.070
-
Targeted therapy of VEGFR2 and EGFR significantly inhibits growth of anaplastic thyroid cancer in an orthotopic murine model. Clin Cancer Res. 2011 Apr 15; 17(8):2281-91.
Score: 0.050
-
Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancer. Mol Cancer Ther. 2010 Jul; 9(7):2057-67.
Score: 0.048
-
Development of a rational strategy for integration of lactate dehydrogenase A suppression into therapeutic algorithms for head and neck cancer. Br J Cancer. 2021 05; 124(10):1670-1679.
Score: 0.025
-
Monitoring of intracerebellarly-administered natural killer cells with fluorine-19 MRI. J Neurooncol. 2019 May; 142(3):395-407.
Score: 0.022
-
Metabolic interrogation as a tool to optimize chemotherapeutic regimens. Oncotarget. 2017 Mar 14; 8(11):18154-18165.
Score: 0.019
-
Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models. Clin Cancer Res. 2016 Apr 01; 22(7):1687-98.
Score: 0.017
-
Tumor T1 Relaxation Time for Assessing Response to Bevacizumab Anti-Angiogenic Therapy in a Mouse Ovarian Cancer Model. PLoS One. 2015; 10(6):e0131095.
Score: 0.017
-
Glycolytic inhibition alters anaplastic thyroid carcinoma tumor metabolism and improves response to conventional chemotherapy and radiation. Mol Cancer Ther. 2012 Jun; 11(6):1373-80.
Score: 0.014
-
TRAIL and doxorubicin combination induces proapoptotic and antiangiogenic effects in soft tissue sarcoma in vivo. Clin Cancer Res. 2010 May 01; 16(9):2591-604.
Score: 0.012
-
Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma. Neuro Oncol. 2010 Jun; 12(6):559-69.
Score: 0.012
-
The 3p21.3 tumor suppressor NPRL2 plays an important role in cisplatin-induced resistance in human non-small-cell lung cancer cells. Cancer Res. 2006 Oct 01; 66(19):9682-90.
Score: 0.009